UBS O'Connor’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-5,850,120
Closed -$230M 702
2023
Q2
$230M Buy
+5,850,120
New +$206M 4.85% 4
2022
Q3
Sell
-109,750
Closed -$1.06M 1029
2022
Q2
$1.06M Buy
+109,750
New +$1.38M 0.01% 753
2016
Q3
Sell
-20,000
Closed -$1.02M 516
2016
Q2
$1.02M Buy
20,000
+10,146
+103% +$504K 0.02% 301
2016
Q1
$417K Buy
+9,854
New +$502K 0.01% 370

UBS O'Connor's ISEE Position: Q3 2023 in Review

UBS O'Connor sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 5,850,120 shares — an estimated $230M sold.

UBS O'Connor first reported a position in ISEE in Q1 2016 and held it in 4 quarters. The position peaked at $230M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

  • UBS O'Connor reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS O'Connor sold 5,850,120 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $230M.
  • UBS O'Connor first reported a position in IVERIC bio, Inc. Common Stock in Q1 2016 and held it in 4 quarters.
  • UBS O'Connor's IVERIC bio, Inc. Common Stock position peaked at $230M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.